Generic Vizimpro Availability

Last updated on Apr 10, 2025.

Vizimpro is a brand name of dacomitinib, approved by the FDA in the following formulation(s):

VIZIMPRO (dacomitinib - tablet;oral)

• Manufacturer: PFIZER
  Approval date: September 27, 2018
  Strength(s): 15MG ^[RLD], 30MG ^[RLD], 45MG ^[RLD]

Is there a generic version of Vizimpro available?

No. There is currently no therapeutically equivalent version of Vizimpro available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vizimpro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Method for treating gefitinib resistant cancer
  Patent 10,596,162
  Issued: March 24, 2020
  Inventor(s): Haber; Daniel A. et al.
  Assignee(s): Wyeth LLC (New York, NY); The General Hospital Corporation (Boston, MA)
  

  The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.

  Patent expiration dates:

  • February 2, 2026
    
    ✓ 
    Patent use: ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OR ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION WITH T790M MUTATION
• Method for treating gefitinib resistant cancer
  Patent 10,603,314
  Issued: March 31, 2020
  Inventor(s): Haber; Daniel A. et al.
  Assignee(s): The General Hospital Corporation (Boston, MA); Wyeth LLC (New York, NY)
  

  The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

  Patent expiration dates:

  • February 2, 2026
    
    ✓ 
    Patent use: ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION
• 4-phenylamino-quinazolin-6-yl-amides
  Patent 7,772,243
  Issued: August 10, 2010
  Inventor(s): Fakhoury; Stephen Alan et al.
  Assignee(s): Warner-Lambert Company LLC (Morris Plains, NJ)
  

  This invention provides quinazoline compounds of the formula: ##STR00001## wherein: R.sub.1 is halo; R.sub.2 is H or halo; R.sub.3 is a) C.sub.1-C.sub.3 alkyl, optionally substituted by halo; or b) --(CH.sub.2).sub.n-morpholino, --(CH.sub.2).sub.n-piperidine, --(CH.sub.2).sub.n-piperazine, --(CH.sub.2).sub.n---piperazine-N(C.sub.1-C.sub.3 alkyl), --(CH.sub.2).sub.n-pyrrolidine, or --(CH.sub.2).sub.n-imidazole; n is 1 to 4; R.sub.4 is --(CH.sub.2).sub.m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C.sub.1-C.sub.3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH.sub.2, NH(C.sub.1-C.sub.3 alkyl) or N (C.sub.1-C.sub.3 alkyl).sub.2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.

  Patent expiration dates:

  • May 5, 2028
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• 4-phenylamino-quinazolin-6-yl-amides
  Patent 8,623,883
  Issued: January 7, 2014
  Inventor(s): Fakhoury Stephen Alan & Lee Helen Tsenwhei & Reed Jessica Elizabeth & Schlosser Kevin Matthew & Sexton Karen Elaine & Tecle Haile & Winters Roy Thomas
  Assignee(s): Warner-Lambert Company LLC
  

  This invention provides quinazoline compounds of the formula:

  Patent expiration dates:

  • May 5, 2025
    
    ✓ 
    Patent use: FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • September 27, 2025 - INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
  • September 27, 2025 - FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer